A Research Study Comparing a New Medicine Oral Semaglutide to Placebo in People With Type 2 Diabetes

NCT04109547 on ClinicalTrials.gov · last registry update 2024-09-19

Finished 23 September 2021, after enrolling 521 people. Primary outcome, as filed: Change From Baseline in Glycosylated Haemoglobin (HbA1c). semaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P3
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Novo Nordisk A/S
Sponsor type: Industry
Enrollment: 521
Started: 2019-10-01
Primary completion: 2021-09-23 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change From Baseline in Glycosylated Haemoglobin (HbA1c)

Conditions studied

Diabetes Mellitus, Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.